

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): November 17, 2025**

**SALARIUS PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-36812**

(Commission File Number)

**46-5087339**

(IRS Employer Identification Number)

**2450 Holcombe Blvd.**

**Suite X**

**Houston, TX**

(Address of principal executive offices)

**77021**

(Zip Code)

**(713) 913-5608**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading Symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.0001	SLRX	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD**

On November 17, 2025, Salarius Pharmaceuticals, Inc. (the “Company”) became aware that certain financial market data platforms, including Yahoo Finance and CapIQ, published information stating that the Company had been delisted from the Nasdaq Capital Market effective November 13, 2025. This information is inaccurate. The Company’s common stock continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol “SLRX”. The Company has contacted these platforms to correct this inaccurate information.

As previously disclosed, on September 4, 2025, the Company received a letter from the Nasdaq Hearings Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Subsequently, on October 10, 2025, the Company received a letter from the Hearings Panel notifying the Company that it had regained compliance with Nasdaq Listing Rule 5550(b)(1) (the “Equity Standard”). On November 13, 2025, the Company announced that it had completed its strategic merger transaction with Decoy Therapeutics, Inc. Following consummation of the merger, the Company continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol “SLRX.” The Company has not received any notification from Nasdaq indicating that it is not compliant with the continued listing requirements of the Nasdaq Capital Market.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.

Date: November 17, 2025

By: /s/ Mark J. Rosenblum  
Mark J. Rosenblum  
Executive Vice President & Chief Financial Officer